Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. more
Time Frame | GKOS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.21% | 2.44% | 2.57% |
1-Month Return | 8.48% | -4.49% | 0.09% |
3-Month Return | 19.76% | -8.82% | 4.76% |
6-Month Return | 30.87% | -4.46% | 9.89% |
1-Year Return | 91.34% | 3.16% | 26.47% |
3-Year Return | 229.67% | -0.83% | 25.98% |
5-Year Return | 175.58% | 35.65% | 86.34% |
10-Year Return | 389.01% | 101.94% | 189.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 236.98M | 224.96M | 294.01M | 282.86M | 314.71M | [{"date":"2019-12-31","value":75.3,"profit":true},{"date":"2020-12-31","value":71.48,"profit":true},{"date":"2021-12-31","value":93.42,"profit":true},{"date":"2022-12-31","value":89.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 38.59M | 91.72M | 66.63M | 68.98M | 75.58M | [{"date":"2019-12-31","value":42.07,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":72.64,"profit":true},{"date":"2022-12-31","value":75.21,"profit":true},{"date":"2023-12-31","value":82.4,"profit":true}] |
Gross Profit | 198.40M | 133.24M | 227.38M | 213.88M | 239.14M | [{"date":"2019-12-31","value":82.96,"profit":true},{"date":"2020-12-31","value":55.72,"profit":true},{"date":"2021-12-31","value":95.09,"profit":true},{"date":"2022-12-31","value":89.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 83.72% | 59.23% | 77.34% | 75.61% | 75.99% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.75,"profit":true},{"date":"2021-12-31","value":92.38,"profit":true},{"date":"2022-12-31","value":90.32,"profit":true},{"date":"2023-12-31","value":90.77,"profit":true}] |
Operating Expenses | 248.69M | 256.79M | 290.26M | 316.20M | 367.84M | [{"date":"2019-12-31","value":67.61,"profit":true},{"date":"2020-12-31","value":69.81,"profit":true},{"date":"2021-12-31","value":78.91,"profit":true},{"date":"2022-12-31","value":85.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (50.29M) | (123.55M) | (62.87M) | (102.31M) | (128.70M) | [{"date":"2019-12-31","value":-5029200000,"profit":false},{"date":"2020-12-31","value":-12355300000,"profit":false},{"date":"2021-12-31","value":-6287200000,"profit":false},{"date":"2022-12-31","value":-10231300000,"profit":false},{"date":"2023-12-31","value":-12870000000,"profit":false}] |
Total Non-Operating Income/Expense | 860.00K | (20.50M) | (28.48M) | (27.46M) | (9.50M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2383.37,"profit":false},{"date":"2021-12-31","value":-3311.51,"profit":false},{"date":"2022-12-31","value":-3193.14,"profit":false},{"date":"2023-12-31","value":-1104.19,"profit":false}] |
Pre-Tax Income | (50.04M) | (132.31M) | (49.27M) | (98.43M) | (133.73M) | [{"date":"2019-12-31","value":-5003600000,"profit":false},{"date":"2020-12-31","value":-13231400000,"profit":false},{"date":"2021-12-31","value":-4926700000,"profit":false},{"date":"2022-12-31","value":-9842900000,"profit":false},{"date":"2023-12-31","value":-13372700000,"profit":false}] |
Income Taxes | (65.46M) | (11.97M) | 326.00K | 766.00K | 934.00K | [{"date":"2019-12-31","value":-7008.57,"profit":false},{"date":"2020-12-31","value":-1281.16,"profit":false},{"date":"2021-12-31","value":34.9,"profit":true},{"date":"2022-12-31","value":82.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 15.42M | (120.35M) | (49.59M) | (99.19M) | (134.66M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-780.26,"profit":false},{"date":"2021-12-31","value":-321.53,"profit":false},{"date":"2022-12-31","value":-643.12,"profit":false},{"date":"2023-12-31","value":-873.06,"profit":false}] |
Income From Continuous Operations | 15.42M | (120.35M) | (49.59M) | (99.19M) | (134.66M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-780.26,"profit":false},{"date":"2021-12-31","value":-321.53,"profit":false},{"date":"2022-12-31","value":-643.12,"profit":false},{"date":"2023-12-31","value":-873.06,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 15.42M | (120.35M) | (49.59M) | (99.19M) | (134.66M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-780.26,"profit":false},{"date":"2021-12-31","value":-321.53,"profit":false},{"date":"2022-12-31","value":-643.12,"profit":false},{"date":"2023-12-31","value":-873.06,"profit":false}] |
EPS (Diluted) | (0.98) | (1.96) | (0.84) | (2.19) | (2.27) | [{"date":"2019-12-31","value":-98,"profit":false},{"date":"2020-12-31","value":-196,"profit":false},{"date":"2021-12-31","value":-84,"profit":false},{"date":"2022-12-31","value":-219,"profit":false},{"date":"2023-12-31","value":-227,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GKOS | |
---|---|
Cash Ratio | 3.66 |
Current Ratio | 5.54 |
Quick Ratio | 4.71 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GKOS | |
---|---|
ROA (LTM) | -7.74% |
ROE (LTM) | -26.10% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GKOS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GKOS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 23.14 |
P/B | 12.47 |
Price/FCF | NM |
EV/R | 22.85 |
EV/Ebitda | NM |
PEG | 1.64 |
Glaukos Corp (GKOS) share price today is $150.564
Yes, Indians can buy shares of Glaukos Corp (GKOS) on Vested. To buy Glaukos Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GKOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Glaukos Corp (GKOS) via the Vested app. You can start investing in Glaukos Corp (GKOS) with a minimum investment of $1.
You can invest in shares of Glaukos Corp (GKOS) via Vested in three simple steps:
The 52-week high price of Glaukos Corp (GKOS) is $153.5. The 52-week low price of Glaukos Corp (GKOS) is $74.75.
The price-to-earnings (P/E) ratio of Glaukos Corp (GKOS) is
The price-to-book (P/B) ratio of Glaukos Corp (GKOS) is 12.47
The dividend yield of Glaukos Corp (GKOS) is 0.00%
The market capitalization of Glaukos Corp (GKOS) is $8.34B
The stock symbol (or ticker) of Glaukos Corp is GKOS